🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Estrogen Receptor Negative

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer NCT05534438Phase 28 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Stereotactic body radiotherapy A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Effect of Er,Cr:YSGG Sub-Ablative Laser Irradiation on Fissure Caries Prevention in Permanent Molars NCT06826456NA1 site📍 Alexandria Alexandria University · Tests: sub-ablative Er,Cr:YSGG laser, Fluoride varnish application Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) NCT05722795NA1 site📍 Gothenburg Vastra Gotaland Region · Tests: Imatinib 400 MG Oral Tablet Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib NCT06341621Phase 31 site📍 Shanghai Fudan University · Tests: 3-year abemaciclib without chemo, treatment of physician's choice PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Accuracy of the New Injury Severity Score in Evaluating Patients With Blunt Trauma NCT06711276n/a1 site📍 Baghdad Al-Nahrain University Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer NCT06637150Phase 31 site📍 Shanghai Fudan University · Tests: Dalpicilib, endocrine therapy A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer NCT06099769Phase 212 sites📍 Birmingham📍 San Francisco📍 Chicago Memorial Sloan Kettering Cancer Center · Tests: Enzalutamide, Mifepristone, TPC Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208Phase 21 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) NCT05512364Phase 3113 sites📍 Anderlecht📍 Brussels📍 Brussels European Organisation for Research and Treatment of Cancer … · Tests: Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG Estradiol Plus Olaparib for Breast Cancer (PHOEBE) NCT05900895Phase 11 site📍 Lebanon Mary D Chamberlin · Tests: Olaparib, 17b-estradiol The MASTER Study (MAmmary Cancer STatin ER Positive Study) NCT04601116Phase 31 site📍 Aarhus Aarhus University Hospital · Tests: Atorvastatin 80 Mg Oral Tablet, Placebo oral tablet Breast Cancer Evolution During Neoadjuvant Systemic Therapy NCT06681064n/a1 site📍 London Royal Marsden NHS Foundation Trust Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer NCT06665178Phase 21 site📍 Vancouver British Columbia Cancer Agency · Tests: Sacituzumab Govitecan A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer NCT07766018Phase 219 sites📍 Chiba📍 Fukuoka📍 Fukuoka Stemline Therapeutics, Inc. · Tests: Elacestrant Telehealth-Enhanced Asthma Care for Home After the Emergency Room NCT05844891NA1 site📍 Rochester University of Rochester · Tests: Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER), Enhanced Care (EC) Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies NCT07340541Phase 26 sites📍 New Haven📍 Baltimore📍 Rochester UNC Lineberger Comprehensive Cancer Center · Tests: SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery NCT06450873Phase 21 site📍 Scottsdale Mayo Clinic · Tests: Coriolus Versicolor Extract, Questionnaire Administration Thorax vs. Trauma Injury Severity Scores as Outcome Predictors in Chest Trauma NCT06707441n/a1 site📍 Baghdad Al-Nahrain University Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites📍 St Louis📍 East Providence📍 Nashville AstraZeneca · Tests: Camizestrant, Atirmociclib Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer NCT05386108Phase 1, Phase 286 sites📍 Fullerton📍 Los Angeles📍 Urbana Stemline Therapeutics, Inc. · Tests: Elacestrant, Abemaciclib The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) NCT07671924Phase 210 sites📍 Toronto📍 Ajax📍 Burlington Trevi Therapeutics · Tests: NAL ER, Placebo First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites📍 Los Angeles📍 San Francisco📍 Aurora Eli Lilly and Company · Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting NCT06976125NA1 site📍 Cleveland University Hospitals Cleveland Medical Center · Tests: Decision Aid-prediction model Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers NCT05846789Phase 27 sites📍 Atlanta📍 Carmel📍 Indianapolis Kathy Miller · Tests: SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer NCT07524855Phase 16 sites📍 New Haven📍 Sarasota📍 Boston Janssen Research & Development, LLC · Tests: JNJ-101684362 (HLD-0117)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy